Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTHER: Estradiol Therapy in ER+ Metastatic Breast Cancer
NCT05716516Phase 2Recruiting
- Sponsor
- Dartmouth Health
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of estradiol in breast cancer, sponsored by Dartmouth Health. Primary endpoint: Clinical Benefit Rate at 12 months. Started May 2023; status: recruiting.
02
Drugs
estradiol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05716516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716516.